BioSculpture Technology, Inc. IPO to commericialize minimally invasive treatment of diabetes and obesity

BST is developing a patented minimally invasive method and device for the endoscopic removal of visceral or “belly” fat, E ndoscopic V isceral L ipectomy or "EVL" as a new treatment of obesity, metabolic syndrome and type 2 diabetes mellitus. Three U.S. patents have been allowed on both the method and device and numerous others are pending. BST filed its Form 1-A with the S.E.C. to fund EVL development and commercialization and initiate becoming a public company. Bringing this highly disruptive EVL technology to market is BST's highest priority. Interested parties may put in Indications of Interest.  There is also an interim mezzanine convertible bond available to Accredited Investors.